Figure 1.

Associations of cisplatin-based CRT with therapeutic response and survival after pembrolizumab therapy in patients with advanced urothelial carcinoma (UC). (A) Objective response rate (ORR), (B) progression-free survival (PFS), and (C) overall survival (OS) are compared between CRT (n = 8) and Non-CRT (n = 18) groups. (D) Comparison of OS curves between CRT (n = 8) and Non-CRT (n = 10) groups in 18 bladder cancer patients. The p-value is calculated by the chi-square test for ORR and the log-rank test for PFS and OS. Asterisks indicate p-values comparing two groups, as indicated in the figure. NS, not significant; * p < 0.05.